Examining MRI Features to Improve Prostate Cancer Diagnosis
Exploring the Correlation Between MRI Image Characteristics and Diagnosis, Pathology and Prognosis in Patients With Prostate Lesions
This study is trying to see if special MRI pictures can help doctors better diagnose prostate cancer in men with high PSA levels or abnormal exams, aiming to reduce unnecessary biopsies and improve patient care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06946771 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between MRI image characteristics and the diagnosis, pathology, and prognosis of prostate lesions in patients. It focuses on men with elevated prostate-specific antigen (PSA) levels or abnormal digital rectal examinations, utilizing advanced multiparametric MRI techniques to enhance the accuracy of prostate cancer detection. By analyzing MRI data, the study seeks to reduce unnecessary biopsies and improve patient outcomes. Participants will be recruited from Tongji Hospital in Wuhan, China.
Who should consider this trial
Good fit: Ideal candidates for this study are adult males with elevated PSA levels or abnormal findings on digital rectal examinations.
Not a fit: Patients who have already undergone prostate biopsy or other anti-tumor treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prostate cancer diagnoses and reduce the number of unnecessary biopsies for patients.
How similar studies have performed: Previous studies have shown that multiparametric MRI can significantly improve the detection rate of prostate cancer, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with abnormal prostate-specific antigen (PSA) elevated (\>4.0 ng/ml) or abnormal digital rectal examination (DRE) or suspicious lesions found by prostate ultrasound, CT or MRI in the hospital 2. Age/Gender: Adult male 3. Patients who voluntarily participate in clinical trials and sign a written informed consent form for subjects Exclusion Criteria: 1. Patients with pacemakers, unknown materials, metal implants in the body, neurostimulators, and claustrophobia 2. Patients who underwent biopsy, local ablation, prostate surgery, or endocrine therapy, chemotherapy, radiotherapy and other anti-tumor treatments before examination
Where this trial is running
Wuhan, Hubei
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Zhen Li
- Email: zhenli@hust.edu.cn
- Phone: 02783663543
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.